Evaluation of the effectiveness of 7% plus hypertonic saline in comparison with 7% hypertonic saline in reducing the growth of Pseudomonas aeruginosa in lung of the patient with cystic fibrosis disease. - Recruiting
ongoing trials trial from other registries
Details- 2021
The effect of compound honey syrup on clinical manifestations of chronic sinusitis in cystic fibrosis (CF) patients - Recruiting
ongoing trials trial from other registries
Details- 2021
A Phase 3b Open-label Study Evaluating the Effects of Elexacaftor/Tezacaftor/Ivacaftor on Cough and Physical Activity in Cystic Fibrosis Subjects 12 Years of Age and Older Who Are Heterozygous for the F508delMutation and a Minimal Function Mutation (F/MF)
ongoing trials trial from other registries
Details- 2021
A randomized, open-label, active controlled, parallel group, multicenter phase 3 study to evaluate the efficacy and tolerability of Bamlanivimab and Etesevimab, Casirivimab and Imdevimab, and Sotrovimab versus Standard of Care in patients with mild to moderate COVID-19 disease (AntiCov)
ongoing trials trial from other registries
Details- 2021
Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 Combination Therapy in Adult Participants With Cystic Fibrosis - Phase 2 - Not yet recruiting
ongoing trials trial from www.clinicaltrials.gov
Details- 2021
- AbbVie
GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance - Phase 2 - Not yet recruiting
ongoing trials trial from www.clinicaltrials.gov
Details- 2021
- University of Pennsylvania|Children's Hospital of Philadelphia
A Phase 3b Open-label Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor Combination Therapy in Subjects With Cystic Fibrosis
ongoing trials trial from other registries
Details- 2020
Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic Fibrosis - Phase 1|Phase 2 - Recruiting
ongoing trials trial from www.clinicaltrials.gov
Details- 2020
- Armata Pharmaceuticals, Inc.|Cystic Fibrosis Foundation
Effect of Postprandial Insulin Administration of Faster-acting Insulin Analogue Versus Pre-prandial Administration of Acting-insulin Analogue in Cystic Fibrosis Related Diabetes - Phase 4 - Not yet recruiting
ongoing trials trial from www.clinicaltrials.gov
Details- 2020
- University Hospital, Strasbourg, France
A Phase 3b Open-label Study to Assess the Effect of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance in Cystic Fibrosis Subjects with Abnormal Glucose Metabolism
ongoing trials trial from other registries
Details- 2020